New hope for recurrent endometrial cancer: drug combo shows promise
NCT ID NCT06532539
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with endometrial cancer that has come back or spread to a few other spots. It tests a new drug called cadonilimab given together with standard chemotherapy and radiation. The goal is to see if this combination can shrink tumors and help people live longer without the cancer growing. About 30 participants will receive the treatment and be closely monitored for safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Cancer Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
- Can a natural compound boost chemotherapy against endometrial cancer?
- Eating within a 10-Hour window may help prevent a common cancer
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk